Leukemia
<ѻý class="page-description">More in Leukemia
News, features, and commentary about cancer-related issues
-- News, features, and commentary about cancer-related issues
Likelihood of severe maternal morbidity more than 20 times higher versus the general population
10% of patients in trials leading to eli-cel's approval developed MDS or AML
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
Regimen tops best historical response rate with chemoimmunotherapy in this setting
Incidence almost identical to that with standard cancer treatment in randomized trials
Responses to pirtobrutinib observed in patients with previously treated disease
Better survival in one registry study, detriment with class I HLA mismatch in another
Reactions from physician and consumer groups were positive, but drugmakers begged to differ
News, features, and commentary about cancer-related issues
